journal article·2019-02-13

PEG-Detachable Polymeric Micelles Self-Assembled from Amphiphilic Copolymers for Tumor-Acidity-Triggered Drug Delivery and Controlled Release

Mengzhen Xu, Can Yang Zhang, Junguang Wu, Huige Zhou, Ru Bai, Ziyi Shen, Fangling Deng, Ying Liu, Jing Liu

Publisher page

Abstract

The development of an intelligent biomaterial system that can efficiently accumulate at the tumor site and release a drug in a controlled way is very important for cancer chemotherapy. PEG is widely selected as a hydrophilic shell to acquire prolonged circulation time and enhanced accumulation at the tumor site, but it also restrains the cellular transport and uptake and leads to insufficient therapeutic efficacy. In this work, a PEG-detachable pH-responsive polymer that forms micelles from copolymer cholesterol grafted poly(ethylene glycol) methyl ether-Dlabile-poly(β-amino ester)-Dlabile-poly(ethylene glycol) methyl ether (MPEG-Dlabile-PAE-g-Chol) is developed to overcome the aforementioned challenges based on pH value changes among normal physiological, extracellular (pHe), and intracellular (pHi) environments. PEGylated doxorubicin (DOX)-loaded polymeric micelles (DOX-PMs) can accumulate at the tumor site via an enhanced permeability and retention effect, and the PEG shell is detachable induced by cleavage of the pHe-labile linker between the PEG segment and the main chain. Meanwhile, the pHi-sensitive poly(β-amino ester) segment is protonated and has a high positive charge. The detachment of PEG and protonation of PAE facilitate cellular uptake of DOX-PMs by negatively charged tumor cells, along with the escape from endo-/lysosome due to the “proton-sponge” effect. The DOX molecules are controlled release from the carriers at specific pH values. The results demonstrate that DOX-PMs have the capability of showing high therapeutic efficacy and negligible cytotoxicity compared with free DOX in vitro and in vivo. Overall, we anticipate that this PEG-detachable and tumor-acidity-responsive polymeric micelle can mediate effective and biocompatible drug delivery “on demand” with clinical application potential.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Polymer Synthesis and Characterization · Hydrogels: synthesis, properties, applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, University of Chinese Academy of Sciences, Beijing 100190, China

Center for Nanoscale Science and Technology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China

The College of Life Sciences, Northwest University (NWU), Xi’an 710069, China

Wuhan University, Hubei 430072, China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (70)

Show source-provided references
1. 10.1016/j.jconrel.2011.01.03010.1016/j.jconrel.2011.01.030 ↗
2. 10.1016/j.jconrel.2015.03.01810.1016/j.jconrel.2015.03.018 ↗
3. 10.1016/j.biomaterials.2015.05.00710.1016/j.biomaterials.2015.05.007 ↗
4. 10.1002/adma.20120083210.1002/adma.201200832 ↗
5. 10.1016/j.semcancer.2018.04.00710.1016/j.semcancer.2018.04.007 ↗
6. 10.1001/jamaoncol.2018.120910.1001/jamaoncol.2018.1209 ↗
7. 10.1177/175883401774257610.1177/1758834017742576 ↗
8. 10.1021/acsnano.5b0201710.1021/acsnano.5b02017 ↗
9. 10.1016/S0169-409X(00)00124-110.1016/S0169-409X(00)00124-1 ↗
10. 10.7326/0003-4819-80-2-24910.7326/0003-4819-80-2-249 ↗
11. 10.7326/0003-4819-125-1-199607010-0000810.7326/0003-4819-125-1-199607010-00008 ↗
12. 10.1016/j.jconrel.2016.06.00310.1016/j.jconrel.2016.06.003 ↗
13. 10.1038/nmat377610.1038/nmat3776 ↗
14. 10.1002/adma.20100465810.1002/adma.201004658 ↗
15. 10.1002/adma.20150157810.1002/adma.201501578 ↗
16. 10.1002/adma.20100016510.1002/adma.201000165 ↗
17. 10.1002/adfm.20110275610.1002/adfm.201102756 ↗
18. 10.1002/adma.20170543610.1002/adma.201705436 ↗
19. 10.1002/adma.20160535710.1002/adma.201605357 ↗
20. 10.1016/j.biomaterials.2013.02.07110.1016/j.biomaterials.2013.02.071 ↗
21. 10.1016/j.jconrel.2016.06.00910.1016/j.jconrel.2016.06.009 ↗
22. 10.1016/j.addr.2006.09.02010.1016/j.addr.2006.09.020 ↗
23. 10.1016/j.colsurfb.2016.02.04510.1016/j.colsurfb.2016.02.045 ↗
24. 10.1021/acsami.6b0200610.1021/acsami.6b02006 ↗
25. 10.1002/adma.20110406610.1002/adma.201104066 ↗
26. 10.1002/adma.20110035110.1002/adma.201100351 ↗
27. 10.1126/science.108362510.1126/science.1083625 ↗
28. 10.1016/j.addr.2012.01.02010.1016/j.addr.2012.01.020 ↗
29. 10.1016/j.jconrel.2010.09.00310.1016/j.jconrel.2010.09.003 ↗
30. 10.1080/1061186050037674110.1080/10611860500376741 ↗
31. Gabizon A. · Cancer Res. · 1994 · 54 · 987
32. 10.1039/C4PY00575A10.1039/C4PY00575A ↗
33. 10.2174/15672010577437026710.2174/156720105774370267 ↗
34. 10.1016/j.nano.2010.05.00510.1016/j.nano.2010.05.005 ↗
35. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
36. 10.1007/s11705-016-1582-210.1007/s11705-016-1582-2 ↗
37. 10.1016/j.biomaterials.2012.05.02510.1016/j.biomaterials.2012.05.025 ↗
38. 10.1016/j.jmgm.2016.01.01010.1016/j.jmgm.2016.01.010 ↗
39. 10.1021/acs.macromol.5b0042310.1021/acs.macromol.5b00423 ↗
40. 10.1016/j.eurpolymj.2008.08.01710.1016/j.eurpolymj.2008.08.017 ↗
41. 10.1016/j.addr.2012.09.00810.1016/j.addr.2012.09.008 ↗
42. 10.1002/ange.20150950710.1002/ange.201509507 ↗
43. 10.1021/jacs.5b0960210.1021/jacs.5b09602 ↗
44. 10.1002/anie.20090267210.1002/anie.200902672 ↗
45. 10.1021/nn301148e10.1021/nn301148e ↗
46. 10.1016/j.jconrel.2014.02.01510.1016/j.jconrel.2014.02.015 ↗
47. 10.3109/1061186X.2015.102042810.3109/1061186X.2015.1020428 ↗
48. 10.1021/acs.jpcb.5b1112510.1021/acs.jpcb.5b11125 ↗
49. 10.1021/jacs.6b0483110.1021/jacs.6b04831 ↗
50. 10.1021/acs.molpharmaceut.6b0000410.1021/acs.molpharmaceut.6b00004 ↗
51. 10.1002/adfm.20150525210.1002/adfm.201505252 ↗
52. 10.1016/j.ab.2004.12.02610.1016/j.ab.2004.12.026 ↗
53. 10.1002/smll.20140286510.1002/smll.201402865 ↗
54. 10.1021/bm701084w10.1021/bm701084w ↗
55. 10.1021/ja001538810.1021/ja0015388 ↗
56. 10.1016/j.colsurfb.2016.02.02510.1016/j.colsurfb.2016.02.025 ↗
57. 10.1021/bc800563g10.1021/bc800563g ↗
58. 10.1002/1521-3773(20010504)40:9<1707::AID-ANIE17070>3.0.CO;2-F10.1002/1521-3773(20010504)40:9<1707::AID-ANIE17070>3.0.CO;2-F ↗
59. 10.2147/IJN.S6949310.2147/IJN.S69493 ↗
60. 10.1016/j.biomaterials.2008.11.02710.1016/j.biomaterials.2008.11.027 ↗
61. 10.1039/C5NR01084E10.1039/C5NR01084E ↗
62. 10.1039/C4RA06413E10.1039/C4RA06413E ↗
63. 10.1016/j.nano.2008.09.00310.1016/j.nano.2008.09.003 ↗
64. 10.1002/aic.1211910.1002/aic.12119 ↗
65. 10.1016/S0169-409X(01)00112-010.1016/S0169-409X(01)00112-0 ↗
66. 10.1016/j.ijpharm.2005.05.02510.1016/j.ijpharm.2005.05.025 ↗
67. 10.1016/j.cej.2009.03.04910.1016/j.cej.2009.03.049 ↗
68. 10.1021/acsami.6b0424710.1021/acsami.6b04247 ↗
69. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
70. 10.1016/j.jconrel.2014.03.05710.1016/j.jconrel.2014.03.057 ↗